BridgeBio Pharma, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| March 31,2026 · December 31,2025 | |||
|---|---|---|---|
| (Unaudited) | (1) | ||
| Assets | |||
| Current assets: | |||
| Cash and cash equivalents | $879,891 | $570,119 | |
| Marketable securities | 60,295 | 17,363 | |
| Accounts receivable, net | 205,226 | 139,444 | |
| Inventories | 32,980 | 26,753 | |
| Prepaid expenses and other current assets | 62,914 | 44,070 | |
| Total current assets | 1,241,306 | 797,749 | |
| Equity method investments | 61,529 | 79,972 | |
| Property and equipment, net | 4,941 | 5,366 | |
| Operating lease right-of-use assets | 17,226 | 8,149 | |
| Intangible assets, net | 27,359 | 28,077 | |
| Other assets | 18,620 | 16,712 | |
| Total assets | $1,370,981 | $936,025 | |
| Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders’ Deficit | |||
| Current liabilities: | |||
| Accounts payable | $29,058 | $36,228 | |
| Accrued compensation and benefits | 39,338 | 76,703 | |
| Accrued research and development liabilities | 54,430 | 41,436 | |
| Operating lease liabilities, current portion | 4,439 | 6,192 | |
| Deferred revenue, current portion | 6,115 | 7,190 | |
| 2027 Notes, net | 547,483 | — | |
| Other current liabilities (2) | 135,509 | 120,222 | |
| Total current liabilities | 816,372 | 287,971 | |
| 2033 Notes, net | 619,631 | — | |
| 2031 Notes, net | 565,045 | 564,565 | |
| 2029 Notes, net | 741,402 | 740,890 | |
| 2027 Notes, net | — | 547,015 | |
| Deferred royalty obligations, net (3) | 871,185 | 855,030 | |
| Operating lease liabilities, net of current portion | 14,216 | 3,811 | |
| Deferred revenue, net of current portion | 11,776 | 13,080 | |
| Other long-term liabilities | 229 | 244 | |
| Total liabilities | 3,639,856 | 3,012,606 | |
| Commitments and contingencies (Note 7) | |||
| Redeemable convertible noncontrolling interests | (951) | (570) | |
| Stockholders’ deficit: | |||
| Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding | — | — | |
| Common stock, $0.001 par value; 500,000,000 shares authorized; 204,386,699 shares issued and 195,707,702 shares outstanding as of March 31, 2026; 202,369,129 shares issued and 194,771,957 shares outstanding as of December 31, 2025 | 204 | 202 | |
| Treasury stock, at cost; 8,678,997 shares as of March 31, 2026; 7,597,172 shares as of December 31, 2025 | (405,776) | (323,276) | |
| Additional paid-in capital | 2,112,454 | 2,057,646 | |
| Accumulated other comprehensive income (loss) | (8) | 12 | |
| Accumulated deficit | (3,985,237) | (3,821,194) | |
| Total BridgeBio stockholders’ deficit | (2,278,363) | (2,086,610) | |
| Noncontrolling interests | 10,439 | 10,599 | |
| Total stockholders’ deficit | (2,267,924) | (2,076,011) | |
| Total liabilities, redeemable convertible noncontrolling interests and stockholders’ deficit | $1,370,981 | $936,025 | |
(1)The condensed consolidated balance sheet as of December 31, 2025 is derived from the audited consolidated financial statements as of that date.
(2)Including related party amounts of $3,622 and $2,003 as of March 31, 2026 and December 31, 2025, respectively (as described in Note 9).
(3)Including related party amounts of $206,377 and$204,650 as of March 31, 2026 and December 31, 2025, respectively (as described in Note 9).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.